Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Maxime DougadosJames Cheng-Chung WeiRobert LandewéJoachim SieperXenofon BaraliakosFilip Van den BoschWalter P MaksymowychJoerg ErmannJessica A WalshTetsuya TomitaAtul DeodharDésirée Mfm van der HeijdeXiaoqi LiFangyi ZhaoClinton C BertramGaia GalloHilde CarlierLianne S Genslernull null

Published in: Annals of the rheumatic diseases (2019)

NCT02696785/NCT02696798.

Keyphrases

clinical trial
ankylosing spondylitis
study protocol
disease activity
phase ii
randomized controlled trial
rheumatoid arthritis
gestational age
systemic lupus erythematosus
open label
phase iii